Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05137067 · ClinicalTrials.gov registry record · Phase 2
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
A Phase 2 study, sponsored by Optimal Health Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT05137067: Completed Phase 2 study, sponsored by Optimal Health Research.
NCT05137067 is a Phase 2 study that has completed, run by Optimal Health Research. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05137067, a Phase 2 study, has completed, sponsored by Optimal Health Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
Primary Outcome
A summary indicator of health status by assessing 5 domains: physical function, fatigue, pain, emotional distress, and social health to assess change from baseline for improvement or decline.
Interventions
- DIETARY_SUPPLEMENT Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)
- DRUG Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
- DRUG Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-01-20 |
| Est. Completion | 2023-05-25 |
| Phase | Phase 2 |
What the finished NCT05137067 record still lists
NCT05137067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell) is the first listed.
NCT05137067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05137067 about?
NCT05137067 is a clinical study titled "A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.". This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
What is the current status of trial NCT05137067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2021-01-20. Estimated completion is 2023-05-25.
What interventions are being tested in trial NCT05137067?
The interventions under investigation include: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell) (DIETARY_SUPPLEMENT), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo (DRUG), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel). (DRUG).
Who is sponsoring clinical trial NCT05137067?
This trial is sponsored by Optimal Health Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05137067's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI